Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | SNCA | P37840 | 2/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | IGF1R | P08069 | 2/20 | 0.60 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.60 |
| ▸ | DHFR | P00374 | 1/20 | 0.60 |
| ▸ | PLK4 | O00444 | 3/20 | 0.59 |
| ▸ | PLK1 | P53350 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394810 | 1.00 | APP (0.64) | APPMAPTSNCARAF1EGFR | |
| SCHEMBL7979340 | 0.89 | DHFR (0.77) | APPMAPTSNCARAF1EGFR | |
| SCHEMBL7979342 | 0.89 | DHFR (0.77) | APPMAPTSNCARAF1EGFR | |
| SCHEMBL5080407 | 0.84 | LRRK2 (0.67) | RAF1EGFRPDGFRBERBB2NOX4 | |
| SCHEMBL1395025 | 0.84 | LRRK2 (0.67) | RAF1EGFRPDGFRBERBB2NOX4 | |
| SCHEMBL1395136 | 0.79 | RAF1 (1.00) | MAPTRAF1EGFRPDGFRBERBB2 | |
| SCHEMBL5082831 | 0.79 | RAF1 (0.73) | RAF1EGFRPDGFRBERBB2IGF1R | |
| SCHEMBL5083132 | 0.79 | RAF1 (0.71) | APPMAPTSNCARAF1EGFR | |
| SCHEMBL1395134 | 0.79 | RAF1 (1.00) | MAPTRAF1EGFRPDGFRBERBB2 | |
| SCHEMBL5476173 | 0.79 | RAF1 (0.71) | MAPTRAF1EGFRPDGFRBERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | APP 640/4885MAPT 20/4885SNCA 3/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | APP 24/4885MAPT 9/4885SNCA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.